• About Us  > 

ABOUT NOTCH.

Notch Therapeutics is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems.

To broaden the applicability and accessibility of adoptive cell therapies, Notch Therapeutics has developed best-in-class, off-the-shelf, iPSC-derived T cells using our proprietary, small-footprint manufacturing system that allows us to produce synthetic T cells of unprecedented scale and functionality to further the advancement of cellular immunotherapies for patients and their families.

The company employs more than 65 “Notchos” located in three cell therapy centers of excellence: Vancouver, Toronto, and Seattle.

---
 

VANCOUVER, BRITISH COLUMBIA

  • Corporate Headquarters
  • Research and Engineering
  • Systems Biology
 

SEATTLE, WASHINGTON

  • Product Development / Preclinical Sciences
 

TORONTO, ONTARIO

  • Advanced Cell Manufacturing
  • Product Development / Preclinical Sciences

With offices in Vancouver, Seattle, and Toronto, Notch Therapeutics operates on the traditional, ancestral, and unceded territories of the Musqueam, Squamish, and Tsleil-Waututh Nations; the ancestral land of the Duwamish, Suquamish, Stillaguamish, and Muckleshoot people; and the Treaty Lands and Territory of the Mississaugas of the Credit First Nation as well as the traditional territory of the Huron-Wendat and Haudenosaunee peoples. We thank these First Peoples who continue to live on these lands and care for them, and whose relationship to these lands existed long before the founding of Canada or the United States of America.